絞り込み

16646

広告

除染廃棄物の焼却灰 容積減らす新施設完成

福島県内の除染廃棄物を燃やして出る、汚染の程度が高い灰の容積を減らすための新しい施設が、福島第一原発の周辺にある中間貯蔵施設の用地に完成しました。

  1. 新型コロナウイルスに関連した患者の発生に...
  2. コウノトリ5年連続産卵か (デイリースポ...
  3. 音楽教室での著作権料めぐる裁判 あす判決...
  4. 新型ウイルス かかりつけ医が症状の特徴学...

ニュース一覧

Molecular and cellular effects of NEDD8 activating enzyme (NAE) inhibition in myeloma.

著者 McMillin DW , Jacobs HM , Delmore JE , Buon L , Hunter ZR , Monrose V , Yu J , Smith PG , Richardson PG , Anderson KC , Treon SP , Kung AL , Mitsiades CS
Mol Cancer Ther.2012 Jan 12 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

1Medical Oncology, Dana-Farber Cancer Institute.

スターを付ける スターを付ける     (32view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

The NEDD8 activating enzyme (NAE) is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway. NEDD8 modification of cullins is required for ubiquitination of cullin-ring ligases (CRLs), which regulate degradation of a distinct subset of proteins. The more targeted impact of NAE on protein degradation prompted us to study MLN4924, an investigational NAE inhibitor, in preclinical multiple myeloma (MM) models. In vitro treatment with MLN4924 led to dose-dependent decrease of viability (EC50=25-150nM) in a panel of human MM cell lines. MLN4924 was similarly active against a bortezomib-resistant ANBL-6 subline and its bortezomib-sensitive parental cells. MLN4924 had sub-µM activity (EC50 values <500nM) against primary CD138+ MM patient cells and exhibited at least additive effect when combined with dexamethasone, doxorubicin and bortezomib against MM.1S cells. The bortezomib-induced compensatory up-regulation of transcripts for ubiquitin/proteasome was not observed with MLN4924 treatment, suggesting distinct functional roles of NAE vs 20S proteasome. MLN4924 was well tolerated at doses up to 60mg/kg 2x daily and significantly reduced tumor burden in both a subcutaneous and a orthotopic mouse model of MM. These studies provide the framework for the clinical investigation of MLN4924 in MM.
PMID: 22246439 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード